Successful treatment of pleuroperitoneal communication with pleurodesis using autologous blood in a patient with severe heart failure undergoing peritoneal dialysis: a case report and brief literature review

Satoru Tatematsu¹*, Koji Hosoya² and Munekazu Ryuzaki¹

Abstract

Background: Pleuroperitoneal communication is a potential complication of peritoneal dialysis (PD). Of the various treatment strategies for pleuroperitoneal communication, successful treatment with pleurodesis using autologous blood has rarely been reported.

Case presentation: A 58-year-old man with end-stage kidney disease secondary to diabetic nephropathy and severe heart failure was placed on PD. He developed right-sided hydrothorax after the commencement of PD. Technetium-99m macro-aggregated human serum albumin peritoneal scintigraphy revealed pleuroperitoneal communication. PD was temporarily discontinued and substituted with hemodialysis. Subsequently, the levels of pleural fluid decreased. However, the resumption of PD exacerbated the hydrothorax. After thoracentesis, 50 mL of autologous blood was instilled into the right pleural cavity. There were no complications related to the procedure. PD was reinitiated 5 days after pleurodesis. Repeated chest X-rays did not depict any evidence of recurrent hydrothorax over the subsequent 10 months.

Conclusions: Pleurodesis using autologous blood was effective for pleuroperitoneal communication and was evidently safe in our patient. It should be considered in patients with severe heart failure since it is minimally invasive.

Keywords: Autologous blood, Hydrothorax, Peritoneal dialysis, Pleurodesis, Pleuroperitoneal communication, Severe heart failure

* Correspondence: satorutz@gmail.com
¹Division of Nephrology, Department of Internal Medicine, Tokyo Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo 108-0073, Japan
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background

Pleuroperitoneal communication (PPC) is one of the potential complications of peritoneal dialysis (PD). It causes retention of pleural fluid by the transfer of dialysate injected into the abdominal cavity into the thoracic cavity. It is speculated that the mechanisms underlying the development of hydrothorax include the presence of congenital or acquired diaphragmatic defects, bleb rupture in the fragile part of the diaphragm, increased intraabdominal pressure, lymphatic drainage disorders, and malpositioning of a PD catheter [1–6]. Hydrothorax often develops at the beginning of PD and presents chiefly in the right hemithorax [7, 8]. Its incidence reportedly ranges from 1.6 to 10% in patients undergoing PD [9]. Some patients remain asymptomatic, while others experience coughing, dyspnea, chest pain, and/or reduced ultrafiltration. PD must be replaced by hemodialysis in approximately 50% of patients [7, 8].

The treatment for hydrothorax complicating PD includes cessation of treatment, pleurodesis with sclerosing agents, and surgical intervention. However, the ideal management strategy remains undetermined. Pleural adhesion with autologous blood is advantageous, since it is safe and has almost no adverse effects. However, there are few case reports of successful treatment of PPC with autologous blood. Herein, we present a case of PD-related hydrothorax successfully treated using pleurodesis with autologous blood in a patient with severe heart failure.

Case presentation

A 58-year-old man with end-stage kidney disease secondary to diabetic nephropathy and severe heart failure was placed on PD. The PD prescription was three exchanges of 1 L of 2.5% glucose dialysate. He was treated with telmisartan, carvedilol, furosemide, trichlormethiazide, atorvastatin, low-dose aspirin, lansoprazole, ferrous citrate, calcium polystyrene-sulfonate, and bixalomer. He was hospitalized because the chest X-ray revealed right-sided pleural effusion (Fig. 1). Its incidence reportedly ranges from 1.6 to 10% in patients undergoing PD [9]. Some patients remain asymptomatic, while others experience coughing, dyspnea, chest pain, and/or reduced ultrafiltration. PD must be replaced by hemodialysis in approximately 50% of patients [7, 8].

Blood test data on admission

Table 1

| Parameter          | Value  |
|--------------------|--------|
| WBC count          | 7400/mm³ |
| RBC count          | 3.41 × 10⁹/mm³ |
| Hemoglobin         | 10.6 g/dL |
| Hematocrit         | 32.4% |
| Platelet count     | 321000/mm³ |
| Albumin            | 2.7 g/dL |
| Na                 | 146 mEq/L |
| K                  | 4.8 mEq/L |
| Cl                 | 103 mEq/L |
| BUN                | 60 mg/dL |
| Creatinine         | 10.50 mg/dL |
| Uric acid          | 7.2 mg/dL |
| AST                | 14 U/L |
| ALT                | 10 U/L |
| ALP                | 175 U/L |
| γGTP               | 20 U/L |
| Total cholesterol  | 165 mg/dL |
| HDL cholesterol    | 42 mg/dL |
| LDL cholesterol    | 109 mg/dL |
| Triglyceride       | 70 mg/dL |

Table 1 Blood test data on admission

ALP alkaline phosphatase, ALT alanine aminotransferase, AST aspartate aminotransferase, BUN blood urea nitrogen, HDL high-density lipoprotein, LDL low-density lipoprotein, RBC red blood cell, WBC white blood cell, γGTP gamma-glutamyl transferase
Fig. 1 Chest X-ray revealing massive right-sided pleural effusion

Fig. 2 Technetium-99m macro-aggregated human serum albumin peritoneal scintigraphy showing leakage of peritoneal dialysate into the right thoracic cavity
recurrence of hydrothorax was observed on repeated chest X-rays conducted over the subsequent 10 months (Fig. 3).

**Discussion**

Several options exist for treating hydrothorax complicating PD, including interruption of PD, conventional pleurodesis, and surgical intervention. However, to date, no controlled trials comparing different therapeutic approaches have been reported. Therefore, there is no significant data available to guide the choice of therapy, and treatment strategies are based on experts’ opinions and physicians’ preferences [12].

Generally, the management of hydrothorax complicating PD should start with the cessation of PD or reduction of peritoneal dialysate volume. Interruption of PD is evidently associated with a rate of spontaneous resolution of approximately 50% [8]. Therapeutic thoracentesis should be performed if patients develop dyspnea due to moderate to large pleural effusion. In the present case, the first intervention was PD cessation for 11 days, which was ineffective. It is recommended that PD should be suspended for 2–6 weeks [8], suggesting that the approach utilized in the current case would likely have been successful if we had waited longer before recommencing PD.

Conventional pleurodesis is considered when a previous conservative approach is ineffective or recurrent hydrothorax occurs. In the process of pleurodesis, the instillation of sclerosing agents causes inflammation, pleural coagulation-fibrinolysis imbalance, fibroblast proliferation, and collagen production [13], leading to obliteration of PPC. Several agents, such as talc, tetracycline, fibrin glue, OK-432, and autologous blood have been used for pleurodesis for treating PPC [12]. The most efficacious agent has not been determined to date. Chow et al. [8] reviewed 104 consecutive cases of hydrothorax complicating continuous ambulatory peritoneal dialysis (CAPD) and concluded that the success rate of chemical pleurodesis via a thoracostomy tube was only 48%, suggesting that the method is not reliably effective. Autologous blood is believed to be a weak adhesive agent compared with other adhesive agents [14]. However, adhesive agents except for autologous blood often cause side effects such as chest pain, pyrexia, and fibrotic changes in the peritoneum adjacent to the pleura. We opted for autologous blood as an adhesive agent for the present patient because there was a possibility that the side effects reportedly associated with alternative agents may have resulted in deterioration of heart failure. He experienced no side effects and his heart failure did not worsen after pleurodesis using autologous blood.
In contrast with closed pleurodesis, the surgical approach enables the detection and repair of diaphragmatic defects under direct visualization. Diaphragmatic breaches can be sutured with or without reinforcement with patches. Pleurectomy or pleural abrasion can also be conducted during open thoracotomy. In the literature, all cases undergoing open thoracotomy were successful and were able to resume CAPD [8]. Although open thoracotomy has a high success rate, it was deemed inadvisable in the present case due to the associated perioperative risk.

Diagnostic and therapeutic procedures incorporating video-assisted thoracoscopic surgery (VAT) for PPC in a PD patient were first performed in 1996 [15], and it has since become the standard treatment. The approach requires minimal incisions, yet it facilitates direct visualization of the entire diaphragm. VAT surgery enables the direct application of talc, abrasion of the parietal pleura, and closing of flaws in the diaphragm. Two reviews of the relevant published literature suggest that the success rate of treatment with VAT surgery is sufficiently high, ranging from 72 to 88% [8, 16], although it falls short of that of open thoracotomy. Some authors have reported the successful performance of thoracoscopy for talc pleurodesis under local anesthesia [17–19], although general anesthesia is required in most cases. Hemodialysis with an arteriovenous fistula should be avoided in patients with severely impaired cardiac function, such as the present patient; CAPD should be continued, and less invasive procedures should be utilized. Hence, if the treatment using pleurodesis with autologous blood had ultimately failed in the present patient, this approach would have been an appropriate option, considering his cardiac function. There is a concern that conventional pleurodesis may jeopardize the success of subsequent thoracoscopy; however, thoracoscopy can be performed without any complications after conventional pleurodesis with autologous blood [20].

Literature review
Successful treatment of PPC in patients with PD by pleurodesis using autologous blood has rarely been reported [10, 11, 21–23]. A summary of previously reported cases is shown in Table 2.

The volumes of blood instilled each time in previously reported cases range from 40 mL [10, 11, 23] to 100 mL [21, 22]. The number of times successful pleurodesis with autologous blood was performed ranges from one [10, 22] to three times [21]. The duration of PD cessation after the last blood instillation varies widely, from 24 h [22] to 8 weeks [23]. The duration of PD cessation was 5 days in the present case, which is relatively short compared with that in previous reports [10, 11, 23]. However, it has been reported that pleurodesis with autologous blood was successful in cases where PD was discontinued for only 24 h after pleurodesis [22]. Short discontinuation of PD is desirable to avoid intravenous catheter-related adverse events. Hence, we recommended PD 5 days after pleurodesis. No adverse effects such as fever or chest pain were described in the cases reported to date including the present case for pleurodesis with autologous blood.

It has been speculated that blood pleurodesis exhibits its effect via a dual mechanism. Firstly, diaphragmatic breaches are directly sealed by the formation of a clot (sometimes referred to as a blood patch effect). Subsequently, the fibrinogenic activity of the blood generates pleurodesis through pleural irritation and inflammation [24]. Compared with talc powder or tetracycline, autologous blood can more rapidly cease air leaks in patients with persistent air leak because both talc powder and tetracycline are believed only to produce inflammation and scarring with no “patch” effect [25]. The same efficacy would be expected in the treatment of PPC in terms of the time to close flaws in the diaphragm.

The success rate of pleurodesis with autologous blood for PPC is unclear. Some authors have reported that pleurodesis with autologous blood was unsuccessful [20, 21, 26]. Some prospective studies have investigated the efficacy of pleurodesis with autologous blood versus other sclerosants for diseases other than PPC. One randomized controlled trial showed that autologous blood pleurodesis has

| Reference | Age (years) | Sex | Instilled blood volume per time | Number of times | Duration of PD cessation after the last blood instillation | Adverse effects |
|-----------|------------|-----|---------------------------------|----------------|----------------------------------------------------------|---------------|
| 21        | 38         | M   | 100 mL                          | 3              | N.D.                                                     | N.D.          |
| 10        | 24         | F   | 40 mL                           | 1              | 21 days                                                  | None          |
| 11        | 80         | F   | 40 mL                           | 2              | 4 weeks                                                  | None          |
| 22        | 54         | M   | 100 mL                          | 1              | 24 h                                                     | None          |
| 23        | 58         | M   | 40 mL (first time) 50 mL (second time) | 2              | 8 weeks                                                  | None          |
| Present case | 58      | M   | 50 mL                           | 1              | 5 days                                                   | None          |

F female, M male, N.D. not documented, PD peritoneal dialysis

---

Table 2: Clinical features of previously reported pleuroperitoneal communication cases successfully treated by pleurodesis with autologous blood.
equivalent efficacy compared to tetracycline pleurodesis with success rates of 83.4% and 87.5%, respectively, \( (p = 0.36) \) for the treatment of malignant pleural effusion [27].

Another randomized controlled trial showed that autologous blood pleurodesis also has equivalent efficacy compared to talc pleurodesis with success rates of 82.0% and 87.0%, respectively, \( (p = 0.12) \) for the treatment of malignant pleural effusion [28]. Moreover, a prospective study compared the efficacy of autologous blood pleurodesis with talc powder and tetracycline in patients with persistent air leak resulting from primary and secondary spontaneous pneumothorax; the success rates were 75.0%, 84.2%, and 63.6%, respectively, for autologous blood, talc powder, and tetracycline. Thus, the efficacy of autologous blood is comparable to that of talc powder but superior to that of tetracycline [25]. Further studies are needed to clarify if autologous blood pleurodesis has equivalent or superior efficacy for PPC compared with other sclerosing agents.

Conclusions
Here, we described the case of a patient with hydrothorax complicating PD, who was successfully treated with pleurodesis with autologous blood after the failure of temporary cessation of PD. This treatment should be the next choice in patients with severe heart failure if more conservative options fail because it is safe and effective.

Abbreviations
CAPD: Continuous ambulatory peritoneal dialysis; PD: Peritoneal dialysis; PPC: Pleuroperitoneal communication; VAT: Video-assisted thoracoscopy

Acknowledgements
Not applicable.

Authors’ contributions
ST, KH, and MR took care of this patient and decided the treatment. ST drafted the manuscript and is responsible for the final version of the manuscript. All authors read and approved the final manuscript.

Funding
The authors declare that there is no funding related to this manuscript.

Availability of data and materials
The data and materials were all included in the manuscript.

Ethics approval and consent to participate
The case report was written in compliance with the Declaration of Helsinki.

Consent for publication
Written informed consent was obtained from the guardian to publish this case report and any accompanying images. A copy of the written consent form is available for review by the editor of this journal.

Competing interests
The authors declare that they have no competing of interests.

References
1. Saillen P, Mosimann F, Wauters JP. Hydrothorax and end-stage chronic renal failure. Chest. 1991;99:1010–1.
2. Okada H, Ryuzaki M, Kotake S, Nakamoto H, Sugahara S, Kaneko K, et al. Thoracoscopic surgery and pleurodesis for pleuropertitoneal communication in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis. 1999;34:170–2.
3. Tsumura Y, Hatakeyama S, Iwase T, Watanabe G. Video-assisted thoracoscopic surgery for pleuropertitoneal communication in peritoneal dialysis. Eur J Cardio-thoracic Surg. 2001;20:205–7.
4. Yim APC, Lee TW, Wan IFP, Ng C. Pleuropertitoneal fistula. Ann Thorac Surg. 2002;73:1327.
5. Dahle AS, Katyal A, Kharria R. Complications of peritoneal dialysis related to increased intra-abdominal pressure. Adv Perit Dial. 2003;19:130–5.
6. Gorrín MR, Rodríguez-Mendilía N, Saico SP, de Nicolás VD, Roja ME, Quereda C. Hydrothorax secondary to a malpositioned peritoneal dialysis catheter. Perit Dial Int. 2015;35:365–6.
7. Nomoto Y, Sugita T, Nakajima K, Saki H, Osawa G, Ota K, et al. Acute hydrothorax in continuous ambulatory peritoneal dialysis: a collaborative study of 161 centers. Am J Nephrol. 1989;363–7.
8. Chow KM, Szeto CC, Li PTK. Management options for hydrothorax complicating peritoneal dialysis. Semin Dial. 2003;16:839–94.
9. Lou SQ. Hydrothorax: pleural effusion associated with peritoneal dialysis. Perit Dial Int. 2010;30:13–8.
10. Hidai H, Takatsu S, Chiba T. Intrahilar instillation of autologous blood in treating massive hydrothorax following CAPD. Perit Dial Int. 1999;22:1–2.
11. Catzone L, Zuccelli A, Zuccelli P. Hydrothorax in a PD patient: successful treatment with intrapleural autologous blood instillation. Adv Perit Dial. 1991;7:86–90.
12. Szeto CC, Chow KM. Pathogenesis and management of hydrothorax complicating peritoneal dialysis. Curr Opin Pulm Med. 2004;10:315–9.
13. Rodriguez-Panadero F, Montes-Worboys A. Mechanisms of pleurodesis. Respir Physiol. 2012;183:91–8.
14. Mitchem RE, Herndon BL, Fiorella SP, de Nicolás VD, Rioja ME, Gorrín MR, Rodríguez-Mendilía N, Saico SP, de Nicolás VD, Roja ME, Quereda C. Hydrothorax secondary to a malpositioned peritoneal dialysis catheter. Perit Dial Int. 2015;35:365–6.
15. Di Biscaglia M, Paladini P, Voltolini L, Garosi G, Ghiribelli C, Di Paola N, et al. Videothoracoscopic obliteration of pleuropertitoneal fistula in continuous peritoneal dialysis. Ann Thorac Surg. 1996;62:1509–10.
16. Saito M, Nakagawa T, Tokunaga Y, Kondo T. Thoracoscopic surgical treatment for pleuropertitoneal communication. Interact Cardiovasc Thorac Surg. 2012;15:788–9.
17. Mak SK, Chan MW, Tai YP, Wong PN, Lee KF, Fung LH, et al. Thoracoscopic pleurodesis for massive hydrothorax complicating CAPD. Perit Dial Int. 1996;16:421–3.
18. Moreno A, Suria S, Pérez-Valentín MA, Toledo A, Esparza N, García-Cantón C, et al. Hydrothorax in peritoneal dialysis. Effective treatment with pleurodesis. Perit Dial Int. 1998;18:657–8.
19. Kanaan N, Pieters T, Jamar F, Goffin E. Hydrothorax complicating continuous ambulatory peritoneal dialysis: Successful management with talc pleurodesis under thoracoscopy. Nephrol Dial Transplant. 1999;14:1900–2.
20. Nishina M, Iwazaki M, Koizumi M, Masuda R, Kakuta T, Endoh M, et al. A case of peritoneal dialysis-related acute hydrothorax, which was successfully treated by thoracoscopic surgery, using collagen fleec. Tokai J Exp Clin Med. 2011;36:91–4.
21. Sugita T, Matsumoto Y, Nakajima K, Miyazaki M, Kuramoto T, Yano N, et al. Three cases of acute massive hydrothorax complicating continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int. 1989;14:315–9.
22. Okada K, Takahashi S, Kinosita Y. Effect of pleurodesis with autologous blood on hydrothorax due to continuous ambulatory peritoneal dialysis-induced diaphragmatic communication. Nephron. 1993;65:163–4.
23. Scarponi R. Acute hydrothorax in a peritoneal dialysis patient: long-term efficacy of autologous blood cell pleurodesis associated with small-volume peritoneal exchanges. Nephrol Dial Transplant. 2003;18:2200–1.
24. Manley K, Coonar A, Wells F, Scarl M. Blood patch for persistent air leak: A review of the current literature. Curr Opin Pulm Med. 2012;18:333–8.
25. Cobanoglu U, Melik M, Edine M. Autologous blood pleurodesis: a good choice in patients with persistent air leak. Ann Thorac Med. 2009;4:182–6.
26. Chao SH, Tsai TJ. Recurrent hydrothorax following repeated pleurodesis using autologous blood. Perit Dial Int. 1993;13:321–2.
27. Keeratichananont W, Limthon T, Keeratichananont S. Efficacy and safety profile of autologous blood versus tetracycline pleurodesis for malignant pleural effusion. Ther Adv Respir Dis. 2015;9:42–8.
28. Keeratichananont W, Kaewdech A, Keeratichananont S. Efficacy and safety profile of autologous blood versus talc pleurodesis for malignant pleural effusion: a randomized controlled trial. Ther Adv Respir Dis. 2018;12:1–10.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.